Cerebrospinal fluid tau and β-amyloid in Alzheimer patients, disease controls and an age-matched random sample

Neurobiology of Aging

Volumn 27, Issue 9, 2006, Pages 1202-1211

  Ibach, Bernd ^a   Binder, Harald ^a   Dragon, Margarethe ^a   Poljansky, Stefan ^a   Haen, Ekkehard ^a   Schmitz, Eberhard ^b   Koch, Horst ^a   Putzhammer, Albert ^a   Kluenemann, Hans ^a   Wieland, Wolf ^b   Hajak, Goeran ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b Cartias Hospital St Joseph   (Germany)

Author keywords

Amyloid42; Alzheimer's disease; Cerebrospinal fluid; Dementia; Depression; Non Alzheimer dementias; Phosphorylated tau; Psychiatric disorders; Random sample; Schizophrenia; Tau

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; BIOLOGICAL MARKER; TAU PROTEIN;

AGE; AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL ASSESSMENT; COMMUNITY HOSPITAL; CONTROLLED STUDY; CORTICOBASAL DEGENERATION; DEPRESSION; DIAGNOSTIC ACCURACY; DIFFUSE LEWY BODY DISEASE; DISCRIMINANT ANALYSIS; DISEASE CONTROL; ENZYME LINKED IMMUNOSORBENT ASSAY; FRONTOTEMPORAL DEMENTIA; HUMAN; MALE; OUTPATIENT DEPARTMENT; PRIMARY PROGRESSIVE APHASIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN PHOSPHORYLATION; RANDOM SAMPLE; RECEIVER OPERATING CHARACTERISTIC; SCHIZOPHRENIA; SENSITIVITY AND SPECIFICITY;

AGED; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; AREA UNDER CURVE; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; DEMENTIA; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PROSPECTIVE STUDIES; ROC CURVE; SENSITIVITY AND SPECIFICITY; TAU PROTEINS;

EID: 33746003355     PISSN: 01974580     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2005.06.005     Document Type: Article

References (33)

1. Andreasen N., Minthon L., Clarberg A., Davidsson P., Gottfries J., Vanmechelen E., et al. Sensitivity, specificity, and stability of CSF-tau in AD in a community-based patient sample. Neurology 53 (1999) 1488-1494
2. Andreasen N., Minthon L., Davidsson P., Vanmechelen E., Vanderstichele H., Winblad B., et al. Evaluation of CSF-tau and CSF-Aβ42 as diagnostic markers for Alzheimer disease in clinical practice. Arch Neurol 58 (2001) 373-379
3. Andreasen N., Vanmechelen E., Vanderstichele H., Davidsson P., and Blennow K. Cerebrospinal fluid levels of total-tau, phospho-tau and A beta 42 predicts development of Alzheimer's disease in patients with mild cognitive impairment. Acta Neurol Scan (Suppl) 179 (2003) 47-51
4. Buerger K., Teipel S.J., Zinkowski R., Blennow K., Arai H., Engel R., et al. CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects. Neurology 59 (2002) 627-629
5. Chapel H.M., Esiri M.M., and Wilcock G.K. Immunoglobulin and other proteins in the cerebrospinal fluid of patients with Alzheimer's disease. J Clin Pathol 37 (1984) 697-699
6. Clark C.M., Xie S., Chittams J., Ewbank D., Peskind E., Galasko D., et al. Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses?. Arch Neurol 60 12 (2003) 1696-1702
7. Consensus report of the Working Group on: "Molecular and Biochemical Markers of Alzheimer's Disease". The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging Working Group. Neurobiol Aging 1998;19:109-16
8. Galasko D., Chang L., Motter R., Clark C.M., Kaye J., Knopman D., et al. High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. Arch Neurol 55 (1998) 937-945
9. Hampel H., Buerger K., Zinkowski R., Teipel S.J., Goernitz A., Andreasen N., et al. Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study. Arch Gen Psychiatry 61 1 (2004) 95-102
10. Hulstaert F., Blennow K., Ivanoiu A., Schoonderwaldt H.C., Riemenschneider M., De Deyn P.P., et al. Improved discrimination of AD patients using beta-amyloid(1-42) and tau levels in CSF. Neurology 52 8 (1999) 1555-1562
11. Ibach B., Poljansky S., Marienhagen J., Sommer M., Manner P., and Hajak G. Contrasting metabolic impairment in frontotemporal degeneration and early onset Alzheimer's disease. Neuroimage 23 2 (2004) 739-743
12. Ibach B., and Haen E. Acetylcholinesterase inhibition in Alzheimer's Disease. Curr Pharm Des 10 3 (2004) 231-251
13. Itoh N., Arai H., Urakami K., Ishiguro K., Ohno H., Hampel H., et al. Large-scale, multicenter study of cerebrospinal fluid tau protein phosphorylated at serine 199 for the antemortem diagnosis of Alzheimer's disease. Ann Neurol 50 2 (2001) 150-156
14. Jensen M., Schroder J., Blomberg M., Engvall B., Pantel J., Ida N., et al. Cerebrospinal fluid A beta42 is increased early in sporadic Alzheimer's disease and declines with disease progression. Ann Neurol 45 4 (1999) 504-511
15. Kanai M., Matsubara E., Isoe K., Urakami K., Nakashima K., Arai H., et al. Longitudinal study of cerebrospinal fluid levels of tau, A beta1-40, and A beta1-42(43) in Alzheimer's disease: a study in Japan. Ann Neurol 44 1 (1998) 17-26
16. Klunemann H.H., Fronhofer W., Wurster H., Fischer W., Ibach B., and Klein H.E. Alzheimer's second patient: Johann F. and His family. Ann Neurol 52 4 (2002) 520-523
17. Maddalena A., Papassotiropoulos A., Muller-Tillmanns B., Jung H.H., Hegi T., Nitsch R.M., et al. Biochemical diagnosis of Alzheimer disease by measuring the cerebrospinal fluid ratio of phosphorylated tau protein to beta-amyloid peptide42. Arch Neurol 60 (2003) 1202-1206
18. McKeith I.G., Galasko D., Kosaka K., Perry E.K., Dickson D.W., Hansen L.A., et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 47 5 (1996) 1113-1124
19. McKhann G., Drachman D., Folstein M., Katzman R., Price D., and Stadlan E.M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34 (1984) 939-944
20. Morris J.C., Heyman A., Mohs R.C., Hughes J.P., van Belle G., Fillenbaum G., et al. The consortium to establish a registry for Alzheimer's disease (CERAD) Part I. Clinical and neuropsychological assessment of Alzheimer's disease. Neurology 39 (1989) 1159-1165
21. Nakamura T., Shoji M., Harigaya Y., Watanabe M., Hosoda K., Cheung T.T., et al. Amyloid beta protein levels in cerebrospinal fluid are elevated in early-onset Alzheimer's disease. Ann Neurol 36 6 (1994) 903-911
22. Neary D., Snowden J.S., Gustafson L., Passant U., Stuss D., Black S., et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology 51 6 (1998) 1546-1554
23. Neuropathology Group. Medical Research Council Cognitive Function and Aging S: Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales. Neuropathology Group of the Medical Research Council Cognitive Function and Ageing Study (MRC CFAS). Lancet 2001;357:169-75
24. Nishimura T., Takeda M., Nakamura Y., Yosbida Y., Arai H., Sasaki H., et al. Basic and clinical studies on the measurement of tau protein in cerebrospinal fluid as a biological marker for Alzheimer's disease and related disorders: multicenter study in Japan. Methods Find Exp Clin Pharmacol 20 3 (1998) 227-235
25. Pardridge W.M., Vinters H.V., Miller B.L., Tourtellotte W.W., Eisenberg J.B., and Yang J. High molecular weight Alzheimer's disease amyloid peptide immunoreactivity in human serum and CSF is an immunoglobulin G. Biochem Biophys Res Commun 145 (1987) 241-248
26. Riemenschneider M., Wagenpfeil S., Diehl J., Lautenschlager N., Theml T., Heldmann B., et al. Tau and Abeta42 protein in CSF of patients with frontotemporal degeneration. Neurology 58 11 (2002) 1622-1628
27. Shoji M., Matsubara E., Kanai M., Watanabe M., Nakamura T., Tomidokoro Y., et al. Combination assay of CSF tau, A beta 1-40 and A beta 1-42(43) as a biochemical marker of Alzheimer's disease. J Neurol Sci 158 2 (1998) 134-140
28. Shoji M., Matsubara E., Murakami T., Manabe Y., Abe K., Kanai M., et al. Cerebrospinal fluid tau in dementia disorders: a large scale multicenter study by a Japanese study group. Neurobiol Aging 23 3 (2002) 363-370
29. Sjogren M., Vanderstichele H., Agren H., Zachrisson O., Edsbagge M., Wikkelso C., et al. Tau and Abeta42 in cerebrospinal fluid from healthy adults 21-93 years of age: establishment of reference values. Clin Chem 47 10 (2001) 1776-1781
30. Sunderland T., Linker G., Mirza N., Putnam K.T., Friedman D.L., Kimmel L.H., et al. Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. JAMA 289 16 (2003) 2094-2103
31. Vanmechelen E., Vanderstichele H., Davidsson P., Van Kerschaver E., Van Der Perre B., Sjogren M., et al. Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization. Neurosci Lett 285 1 (2000) 49-52
32. World Health Organization: Tenth Revision of the International Classification of Diseases, Chapter V (F): Mental and Behavioural Disorders (including disorders of psychological development). Clinical Descriptions and Diagnostical Guidelines. 2002
33. Zaudig M., Mittelhammer J., Hiller W., Pauls A., Thora C., Morinigo A., et al. SIDAM-a structured interview for the diagnosis of dementia of the Alzheimer type, multi-infarct dementia and dementias of other aetiology according to ICD-10 and DSM-III-R. Psychol Med 21 (1991) 225-236